Status:
COMPLETED
EuRopean Study of MAjor Infectious Disease Syndromes Related to COVID-19
Lead Sponsor:
UMC Utrecht
Conditions:
COVID-19
SARS-CoV 2
Eligibility:
All Genders
Brief Summary
Background Rapid European COVID-19 Emergency Research response (RECoVER), is a project involving 10 international partners that has been selected for funding by the European Union under the Horizon 20...
Eligibility Criteria
Inclusion
- Clinical suspicion of a new episode of acute respiratory tract infection.
- Patient is admitted to hospital
- Primary reason for hospital admission is clinical suspicion of a new episode of ARI
- Onset of the following symptoms within the last 7 days: i. Sudden onset of self-reported fever OR temperature of ≥ 38°C at presentation AND ii. At least one respiratory symptom (cough, sore throat, runny or congested nose, dyspnea) AND iii. At least one systemic symptom (headache, muscle ache, sweats or chills or tiredness)
- OR
- Laboratory confirmed SARS-CoV-2 infection at the time of eligibility check.
Exclusion
- Inability to obtain consent from patient or surrogate
- Previous enrollment in current study
Key Trial Info
Start Date :
June 18 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 16 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04364711
Start Date
June 18 2020
End Date
December 16 2022
Last Update
May 12 2023
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Tartu University
Tartu, Estonia
2
Attikon Hospital
Athens, Greece
3
Brescia Hospital
Brescia, Italy
4
UMC Utrecht
Utrecht, Netherlands